Register
Question 1
How many days does the FDA have to file, or refuse to file, an NDA after receipt?
Correct Answer:
60
Explanation:
The Food and Drug Administration (FDA) is required to review a New Drug Application (NDA) within a specified timeframe to ensure that the development of new drugs is efficient and compliance with regulatory standards is upheld. Upon receiving an NDA, the FDA has 60 days to determine whether to accept the application for review or refuse to file it. During this 60-day period, the FDA assesses whether the application is sufficiently complete for the substantive review process. If the application is found to be lacking critical data or if there are other significant issues, the FDA will refuse to file the application, which halts the process until the applicant addresses the deficiencies. This timeline ensures that drugs do not unnecessarily occupy FDA resources if they do not meet initial regulatory standards, allowing for a focus on applications that are likely to meet the criteria for safety and efficacy.
Question 2
What does "surrogate endpoint" refer to in clinical trials?
Correct Answer:
A substitute measure for a clinically meaningful outcome
Explanation:
A surrogate endpoint refers to a measure that substitutes for a clinically meaningful outcome in clinical trials. This means that it is an indirect indicator that helps researchers assess the effect of a treatment when direct measurement of the intended clinical benefit (such as survival rates or disease progression) may take too long or is impractical. Surrogate endpoints are often laboratory measurements or physical signs that are believed to predict the actual clinical outcomes. For example, evaluating blood pressure as a surrogate endpoint for the risk of heart disease may allow researchers to expedite trials aimed at understanding the overall effectiveness of cardiovascular treatments. While surrogate endpoints can speed up the drug approval process and provide early indications of treatment effects, they must be validated to ensure they accurately reflect the true clinical outcomes they aim to substitute. The other options do not correctly define a surrogate endpoint in the context of clinical trials. A primary measure of drug effectiveness is typically a direct outcome measure rather than a substitute. A type of patient-reported outcome specifically focuses on information reported directly by patients regarding their health status, while a statistical tool relates to methods used for data analysis rather than the conceptualization of clinical measures.
Question 3
For sites conducting clinical trials in the EU, what specific labeling requirement must be met?
Correct Answer:
Labeling must specify the period of use for the product.
Explanation:
The requirement for labeling in clinical trials conducted in the EU includes specifying the period of use for the product, which is essential for ensuring that participants are informed about how long they can safely use the investigational product. This information is crucial for maintaining participant safety and supporting compliance throughout the trial. The period of use helps to prevent potential adverse effects associated with prolonged use beyond the indicated timeframe and informs both participants and investigators about the appropriate duration for which the product is intended to be utilized. It aids in the assessment of the product's effects and provides necessary instructions for managing the trial effectively. While other labeling elements may also be important in various contexts, such as a manufacturer's name or an expiration date, the specific mention of the period of use is critical in the regulatory framework governing clinical trials, emphasizing the importance of participant safety and informed consent within the clinical setting.
Question 4
What is the primary requirement for the lot release of biologics?
Correct Answer:
Quality verification
Explanation:
The primary requirement for the lot release of biologics is quality verification. This involves the assessment and confirmation that each lot of the biologic product meets specific quality standards and regulations established by authorities such as the FDA. Quality verification ensures that the product not only is produced according to the specified manufacturing processes but also aligns with established standards for safety, efficacy, and overall quality. Quality verification typically includes a series of tests and evaluations to assess factors such as the identity, purity, potency, and sterility of the biologic product. This rigorous process is critical because biologics can vary significantly in their composition and activity compared to traditional pharmaceuticals; hence, ensuring consistent quality throughout each production batch is paramount for patient safety and therapeutic effectiveness. While safety and efficacy testing, stability studies, and manufacturing documentation are all essential aspects of the overall regulatory process for biologics, they do not solely encompass the lot release requirements. Safety and efficacy testing is generally conducted during clinical trials and is crucial for obtaining initial approval, but it is not a routine requirement for lot release. Stability studies help to understand how a product behaves over time, which is important for long-term quality assurance but does not directly pertain to the immediate evaluation for lot release. Manufacturing documentation provides necessary insights into the production process
Question 5
What is the minimum duration of continuous use that requires carcinogenicity testing for pharmaceuticals?
Correct Answer:
6 months
Explanation:
The requirement for carcinogenicity testing in pharmaceuticals is primarily based on the duration of exposure necessary to evaluate the potential for carcinogenesis effectively. A minimum duration of continuous use of 6 months is considered the threshold for initiating carcinogenicity studies because it is typically sufficient to allow for the identification of long-term exposure effects, including tumor development. This timeframe aligns with guidelines issued by regulatory authorities, which underscore that testing should be appropriate to capture the relevant biological effects over a period that reflects possible long-term use in humans. Choosing 6 months as the minimum duration considers the balance between ensuring that sufficient data can be gathered while also recognizing that prolonged exposure may not always be feasible in the early clinical phases. Shorter timeframes, such as 3 months, would not generally provide a comprehensive understanding of the potential risks, while durations such as 12 or 18 months might extend beyond what is necessary for initial assessments of safety regarding carcinogenic risks in preclinical stages.
Question 1
Exam overview

About this Exam

The Regulatory Affairs Certification (RAC) is the leading professional credential for regulatory affairs professionals in the healthcare and life sciences sectors. Administered by the Regulatory Affairs Professionals Society (RAPS), the RAC designation demonstrates a high level of expertise in the regulatory frameworks for medical devices, pharmaceuticals, or both. Earning this credential signifies to employers and peers that you possess the critical knowledge necessary to navigate the complex and ever-evolving global regulatory landscape.

The RAC exam is designed for professionals working in regulatory affairs, quality assurance, clinical research, product development, and related fields within the medical device, pharmaceutical, and biotechnology industries. Whether you are early in your career or a seasoned veteran, achieving the RAC credential validates your commitment to the profession and marks you as a knowledgeable leader capable of driving successful product approvals and maintaining compliance.

More details

Additional Information

What the Course Entails and Exam Details

While RAPS does not mandate specific coursework to sit for the exam, the RAC credential is based on a robust Body of Knowledge (BoK). The exam itself tests your ability to apply regulatory knowledge to real-world scenarios across various domains. The specific content depends on the concentration you choose: the RAC (US), RAC (EU), RAC (Canada), or RAC (Global).

However, all RAC exams generally cover core foundational topics, including:

  • The Regulatory Framework: Understanding the roles and responsibilities of regulatory agencies (such as the FDA in the US, EMA in the EU, and Health Canada), as well as international standards like ISO 13485 and ICH guidelines.
  • Product Development: Regulatory considerations during the entire product lifecycle, from initial concept and design control to pre-clinical testing and clinical trials.
  • Pre-Market and Post-Market Activities: The processes for preparing and submitting marketing applications (e.g., 510(k), PMA, MAA) and the ongoing requirements for post-market surveillance, adverse event reporting, labeling, and advertising.
  • Quality Systems and Compliance: Knowledge of Good Manufacturing Practices (GMP), Quality System Regulations (QSR), and the role of regulatory affairs in audits and inspections.

 

 

 

 What to Expect in the Final Exam

The RAC exam is a rigorous, computer-based assessment consisting entirely of multiple-choice questions. The exam is designed to test not only your recall of facts but also your ability to analyze situations and apply regulatory principles.

The specific format, number of questions, and time limits vary slightly depending on the specific RAC credential you are pursuing. Generally, candidates can expect the following:

  • Exam Format: All RAC exams are multiple-choice. You will be presented with scenarios and asked to select the best course of action based on regulations.
  • Number of Questions: The exam typically includes between 150 and 250 questions, though a portion of these may be pre-test questions that do not count toward your final score.
  • Time Limit: You will be given a generous block of time, often between 3.5 and 5 hours, to complete the entire exam.
  • Passing Score: The exam is scored on a scaled system. You must achieve a scaled score of 500 or higher (on a scale of roughly 200 to 800) to pass.
  • Testing Rules: The exam is administered in secure, proctored testing environments (often through a partner like Kryterion or Pearson VUE). Strict rules apply regarding identification, and no personal items are allowed in the testing room.

 

 How to Study and Exam Centers

Effective preparation for the RAC exam requires a strategic approach. Because the exam focuses heavily on applying knowledge, simply memorizing regulations is often insufficient.

Your preparation should include the following strategies:

  • Utilize the RAPS Body of Knowledge (BoK): This is your primary blueprint for the exam. Review the BoK document provided by RAPS to ensure you understand every topic area covered.
  • Study Official References: RAPS publishes a variety of books and study materials that are considered the gold standard for exam preparation, including the Fundamentals of Regulatory Affairs series. Familiarize yourself with the primary guidance documents relevant to your chosen concentration (e.g., FDA guidance documents for RAC US).
  • Take Multiple Practice Tests: This is perhaps the most crucial step. Taking a RAPS RAC practice test multiple times will help you become familiar with the question style, identify knowledge gaps, and improve your time management. Practice tests simulate the actual exam experience and build the stamina needed for the multi-hour test.
  • Join Study Groups or Courses: Many local RAPS chapters or private training providers offer RAC review courses or study groups. Collaborating with peers can provide new perspectives and clarify difficult concepts.

Where and How to Take the Exam:

The RAC exam is primarily administered via computer-based testing at proctored testing centers worldwide. When you register for the exam through the RAPS website, you will be directed to their testing partner’s portal (such as Kryterion). This portal allows you to select a testing location near you and schedule your exam date and time. RAPS also occasionally offers the exam during their annual conferences and events. Be sure to check the official RAPS website for the most current information on testing locations and remote proctoring options if available.

 

 Job Opportunities from the Course

Earning the RAC credential is a significant investment in your career and opens doors to a wide array of advanced roles within the healthcare and life sciences industry. The knowledge gained and validated by the RAC is highly valued by employers, often leading to increased responsibilities and higher earning potential.

This certification unlocks career paths in medical device, pharmaceutical, and biotechnology companies, as well as consulting firms and regulatory agencies.

Specific job titles you can pursue or advance in include:

  • Regulatory Affairs Specialist / Associate
  • Regulatory Affairs Manager / Director
  • Senior Regulatory Affairs Consultant
  • Global Regulatory Lead
  • Regulatory Intelligence Analyst
  • Manager of Regulatory Submissions
  • VP of Regulatory Affairs
  • Quality Assurance and Compliance Specialist
  • Clinical Trial Regulatory Manager
  • Product Development Regulatory Strategist

 

Quiz information

Frequently Asked Questions

The complete question count is available after full access is unlocked.
No fixed duration is currently configured for this quiz.
Question explanations are included where they are available in the quiz content, helping you review the reasoning after answering.
Yes. You can retake the practice test again as you continue studying during your available access period.
After your access is confirmed, you can continue into the complete practice exam from this quiz flow.
Unless explicitly stated otherwise, this page provides independent practice material for study and exam preparation and is not the official examination itself.
Keep studying

Related Questions

RAPS Regulatory Affairs Certification – Drugs (RAC‑Drugs) Practice Test

0 min

Regulatory Affairs Professionals Society (RAPS) Practice Test

0 min

PDAA Vehicle & Fleet Wraps Certification [car-wraps]

0 min

PDAA Vehicle & Fleet Wraps Certification

0 min